2025 PACC Miami | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma
0% Complete
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Nov 23, 2025
- Last Review
- Nov 23, 2025
- Expires
- Nov 23, 2026
Target Audience
Pharmacists
Faculty & Disclosure
Faculty
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Accreditation
NA
